Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AND017 for Anemia in Lower Risk MDS
NCT06304103Phase 2Recruiting
- Sponsor
- Kind Pharmaceuticals LLC
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of AND017 in myelodysplastic syndrome (MDS), anemia, sponsored by Kind Pharmaceuticals LLC. Started Mar 2025; status: recruiting.
02
Drugs
AND017
03
Conditions
myelodysplastic syndrome (MDS)anemia
Beyond the preview
Go deeper on NCT06304103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304103.